Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Shots:

  • Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration
  • Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for which Anima will receive additional payments including ~$1.2B as milestones and royalties
  • Anima will leverage its translation control therapeutics platform to discover novel mRNA translation modulators against the collaboration targets

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: GlobeNewswire

The post Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases first appeared on PharmaShots.